#BoneDisorders
miR-378 promotes ovariectomy-induced bone loss by enhancing osteoclastogenesis and disrupting TGF-β-driven osteogenesis, highlighting miR-378 as a potential therapeutic target for postmenopausal #BoneDisorders. @CAS__Science
#OpenAccess:
MiR-378 mediates the ovariectomy induced bone loss via exaggerating osteoclastogenesis and transforming growth factor beta impaired osteogenesis
Osteoporosis (OP) is a disease characterized by decreased bone mass and damaged architectures. The promising treatment strategy for OP is to inhibit b…
doi.org
June 3, 2026 at 4:44 PM
Ready to update your knowledge on metabolic bone diseases?
ESICON 2025 is honoured to have Dr. Andrew C. Karaplis with expert insights from Canada!

Register Now:https://rxregistrations.com/esicon2025/
📍 ITC Royal Bengal, Kolkata | 🗓️ Sept 4–7

#ESICON2025 #EndocrineUpdates #BoneDisorders
July 31, 2025 at 1:19 PM
This research shows that #FKBP5 promotes ASC #OsteogenicDifferentiation, highlighting the potential of FKBP5 targeted therapies for #BoneDisorders & proposing a controllable strategy for ASC based #Transplantation in #BoneDefect repair. #medsky
Read: doi.org/10.1007/s115...
April 4, 2026 at 11:45 AM